{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:07:50Z","timestamp":1787897270816,"version":"build-2784847793"},"reference-count":88,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Insulin therapy has advanced remarkably over the past few decades. Ultra-rapid-acting and ultra-long-acting insulin analogs are now commercially available. Many additional insulin formulations are in development. This review outlines recent advances in insulin therapy and novel therapies in development.<\/jats:p>","DOI":"10.1089\/dia.2020.0065","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T14:49:31Z","timestamp":1587394171000},"page":"929-936","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":50,"title":["Recent Advances in Insulin Therapy"],"prefix":"10.1177","volume":"22","author":[{"given":"Leah M.","family":"Wilson","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Harold Schnitzer Diabetes Health Center, Oregon Health &amp; Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Castle","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Harold Schnitzer Diabetes Health Center, Oregon Health &amp; Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control and Prevention: National Diabetes Statistics Report 2017: Atlanta GA: Centers for Disease Control and Prevention U.S. Department of Health and Human Services 2017."},{"key":"e_1_3_3_3_2","volume-title":"Diabetes in America","author":"Saydah SH","year":"2017","unstructured":"Saydah SH: Medication use and self care practices in person with diabetes. In: Cowie CC, Casagrande SS, Menke A, et al., eds. Diabetes in America, 3rd ed. Bethesda, MD: National Institutes of Health, 2017.","edition":"3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2009.0112"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1215228"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1205"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1348"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.5008"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0006"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12532"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2015.0290"},{"key":"e_1_3_3_13_2","unstructured":"Tresiba prescribing information: Available at https:\/\/www.novo-pi.com\/tresiba.pdf (accessed January3 2020)."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1668"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3249"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7115"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7117"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615692"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12938"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0559"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05080-9"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13004"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12712"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059524"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30372-3"},{"key":"e_1_3_3_27_2","unstructured":"U.S. Food and Drug Administration: Approval package for: Fiasp 100 units\/mL. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208751Orig1s000Approv.pdf (accessed December13 2019)."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2578-7"},{"key":"e_1_3_3_29_2","unstructured":"U.S. Food and Drug Administration: Inactive ingredient search for approved drug products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm (accessed November27 2019)."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0514-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1771"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1770"},{"key":"e_1_3_3_33_2","unstructured":"Rayhan Lal M Liana Hsu B Marina Basina M Bruce Buckingham M: Fiasp\u00ae (fast-acting insulin aspart) use with a Medtronic 670G system. 19th Annual Diabetes Technology Meeting; November 14\u201316 2019; Bethesda MD."},{"key":"e_1_3_3_34_2","unstructured":"Steven J. Russell M Rabab Jafri M et al.: Use of the ultra-rapid insulin Fiasp in the iLet bionic pancreas. 19th Annual Diabetes Technology Meeting; November 14\u201316 2019; Bethesda MD."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296816658055"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4568903"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0463"},{"key":"e_1_3_3_38_2","unstructured":"U.S. Food and Drug Administration: AFREZZA\u00ae (insulin human) inhalation powder. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022472lbl.pdf (accessed December13 2019)."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0478"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00280-6"},{"key":"e_1_3_3_41_2","unstructured":"Aerami: Our Pipeline. https:\/\/aerami.com\/#pipeline (accessed December13 2019)."},{"key":"e_1_3_3_42_2","unstructured":"Eric Zijlstra P Leona Plum-Moerschel M Marcel Ermer M et al.: Faster absorption and greater early insulin action of Dance 501 inhaled human insulin vs. s.c. insulin lispro in patients with type 2 diabetes. 19th Annual Diabetes Technology Meeting; November 14\u201316 2019; Bethesda MD."},{"key":"e_1_3_3_43_2","unstructured":"Eric Zijlstra P Oliver Klein M Felix Sievers M et al.: Dance 501 inhaled human insulin: lineardose response in patients with type 1 diabetes. 19th Annual Diabetes Technology Meeting; November 14\u201316 2019; Bethesda MD."},{"key":"e_1_3_3_44_2","doi-asserted-by":"crossref","unstructured":"Blevins T Zhang Q Frias JP et al.: Ultra Rapid Lispro improves postprandial glucose control vs. humalog (lispro) in patients with type 2 diabetes: PRONTO-T2D. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-145-OR"},{"key":"e_1_3_3_45_2","doi-asserted-by":"crossref","unstructured":"Bode BW Cao D Liu R et al.: Ultra Rapid Lispro improves postprandial glucose control and time in range in T1D compared with Humalog (lispro): PRONTO-T1D continuous glucose monitoring (CGM) Substudy. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-1089-P"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","unstructured":"Klaff LJ Cao D Dellva MA et al.: Ultra Rapid Lispro improves postprandial glucose control vs. Humalog (lispro) in T1D: PRONTO-T1D Study. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-144-OR"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","unstructured":"Leohr J Dellva MA Coutant DE et al.: Ultra Rapid Lispro accelerates insulin lispro absorption and insulin action vs. Humalog (lispro) in patients with T2D. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-1100-P"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","unstructured":"Linnebjerg H Zhang Q Labell ES et al.: Ultra Rapid Lispro accelerates insulin lispro absorption and insulin action vs. Humalog (lispro) in patients with T1D. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-1107-P"},{"key":"e_1_3_3_49_2","doi-asserted-by":"crossref","unstructured":"Heise T Linnebjerg H Cao D et al.: Ultra Rapid Lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared with other rapid insulin analogs. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.1016\/j.jcjd.2019.07.105"},{"key":"e_1_3_3_50_2","unstructured":"Adocia: BIOCHAPERONE\u00ae LISPRO. https:\/\/www.adocia.com\/products\/biochaperone-ultra-fast-analog-insulin (accessed December13 2019)."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13442"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13621"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13685"},{"key":"e_1_3_3_54_2","doi-asserted-by":"crossref","unstructured":"Pieber TR Howell SJ Jezek J Gerring DJ: Pharmacokinetic and pharmacodynamic properties of a novel \u201csuperfast\u201d insulin aspart formulation. American Diabetes Associations 78th Scientific Sessions; June 22\u201326 2018; Orlando FL.","DOI":"10.2337\/db18-95-LB"},{"key":"e_1_3_3_55_2","unstructured":"Arecor: 5\/12\/2019- Arecor announces positive headline results for the first phase I clinical trial of AT a novel ultra rapid acting formulation of insulin. http:\/\/arecor.com\/news (accessed December13 2019)."},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.39.6.752"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.suppl_3.S233"},{"key":"e_1_3_3_58_2","first-page":"203","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan G","year":"2009","unstructured":"Ryan G, , Briscoe TA, , Jobe L: Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther, 2009; 2:203\u2013214.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0330"},{"key":"e_1_3_3_61_2","first-page":"597","article-title":"A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial","volume":"43","author":"Haidar A","unstructured":"Haidar A, , Tsoukas MA, , Bernier-Twardy S, , Yale JF, , Rutkowski J, , Bossy A, , Pytka E, , El Fathi A, , Strauss N, , Legault L. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial. Diabetes Care 2020 Mar, 1; 43:597\u2013606.","journal-title":"Diabetes Care 2020 Mar"},{"key":"e_1_3_3_62_2","doi-asserted-by":"crossref","unstructured":"Meiffren G Seroussi C Ranson A et al.: BioChaperone Pramlintide Insulin a new co-formulation of pramlintide (pram) and human insulin (ins) improves postprandial blood glucose (BG) vs. both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-150-OR"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","unstructured":"Thohan S Hu WT Donovan MJ et al.: Glycemic control with pramlintide and insulin coformulations: preclinical evaluation of a novel single injection room temperature stable formulation. American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-2483-PUB"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.41574"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1722338115"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0136-y"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2017.1300664"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0598-9"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12852"},{"key":"e_1_3_3_70_2","doi-asserted-by":"crossref","unstructured":"Klonoff DC Bode BW Cohen NJ et al.: Divergent hypoglycemic effects of hepatic directed prandial insulin: a 6-month study in type 1 diabetes mellitus (T1DM). American Diabetes Associations 79th Scientific Sessions; June 7\u201311 2019; San Francisco CA.","DOI":"10.2337\/db19-1084-P"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0152"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10036"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801466"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2006.01.008"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1215"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.2337\/db17-0577"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9306-4"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4636(200111)57:2<151::AID-JBM1154>3.0.CO;2-5"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201300490"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1233-3"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1039\/c2nr30651d"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322651111"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.05.017"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmat2614"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0380-2"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2016.38"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0187"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818778607"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.03.011"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2020.0065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2020.0065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2020.0065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:18:56Z","timestamp":1777400336000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2020.0065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":88,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1089\/dia.2020.0065"],"URL":"https:\/\/doi.org\/10.1089\/dia.2020.0065","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}